Merck KGaA Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations. Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib. AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan. Metabolon, Merck KGaA Form Metabolomics Alliance Metabolon's Precision Metabolomics platform identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways. Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 14 skipping alterations. Nov 19, 2019 Personalis, Merck KGaA to Study Cancer Biomarkers Using Immunogenomics Platform Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Oct 3, 2018 Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic Sep 10, 2018 Definiens, Merck KGaA Partner for Biomarker Discovery Jun 20, 2018 Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations Premium Jan 10, 2018 ThermaGenix, MilliporeSigma Ink PCR Reagents Distribution Deal Dec 27, 2017 HTG Expands Collaboration With Merck KGaA Nov 27, 2017 Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests Sep 26, 2017 FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug Jun 15, 2017 Human Longevity, Merck KGaA Form Cancer Biomarker Partnership Jun 13, 2017 MilliporeSigma's Proxy-CRISPR Tech Aims to Increase Usability of Native CRISPR Proteins Premium May 30, 2017 Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest Premium Apr 11, 2017 MilliporeSigma Developing New Instrument for Single-Molecule Biomarker Detection Premium Jan 6, 2017 Guardant Health, Pharma Firms to Develop 500-Gene Liquid Biopsy Panel Dec 1, 2016 Roche, Merck KGaA Expand PCR Distribution Agreement Nov 30, 2016 Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies Oct 12, 2016 HTG, Merck KGaA Ink CDx Development Deal for Lymphoma Drug Jul 28, 2016 Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market Apr 15, 2016 Expansion of Liquid Biopsy Test Sites Planned by Merck KGaA, Sysmex Premium Apr 7, 2016 Merck KGaA, Sysmex Inostics Garner CE Mark for Liquid Biopsy CRC Test Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.